Ophthalmic Prostaglandin Analog Prior Authorization Criteria
Customize your policy alerts
Sign up for all medimpact policy alerts
Know when medimpact releases new policies or updates existing guidance.
Monitor payer policy activity
This document governs prior authorization criteria and coverage updates for ophthalmic prostaglandin analog agents for Kentucky Medicaid (Fee-for-Service and MCO) members, effective September 1, 2026. It affects pharmacy providers and prescribers submitting PA requests for the listed agents.
Prior authorization criteria updated for preferred and non-preferred ophthalmic prostaglandin analog agents, including specified diagnosis requirements and trial/failure requirements.
Non-preferred agents now require that the patient has had a ≥30-day trial and failure, allergy, contraindication, or intolerance to ≥2 preferred agents.
Preferred agents require a diagnosis of open-angle glaucoma (and for some agents ocular hypertension is included).
Coverage and Prior Authorization Criteria
Initial and step therapy coverage criteria
Coverage updates effective September 1, 2026:
Diagnosis requirement cited in document
Non-preferred agent coverage
- Required prior trials: Patient has had at least a 30‑day trial and failure of two or more preferred prostaglandin agents (can be from any sub-class)>= 30 days; >= 2 preferred agents
Failure, allergy, contraindication (including potential drug–drug interaction), or intolerance to the preferred agents satisfies this requirement
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.